Heron Therapeutics, Inc. — Fiscal 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016, including fourth-quarter results. Heron transitioned to a commercial-stage biotechnology company following FDA approval of SUSTOL on August 9, 2016, with commercial sales beginning in October 2016. The company develops medicines for chemotherapy-induced nausea and vomiting and post-operative pain using its Biochronomer technology.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Net product sales | $1.3 million | $0 |
| Cost of product sales | $35 thousand | $0 |
| Research and development expense | $103.1 million | $61.2 million |
| General and administrative expense | $21.4 million | $18.4 million |
| Sales and marketing expense | $47.7 million | $17.3 million |
| Loss from operations | $(170.9) million | $(96.9) million |
| Net loss | $(173.1) million | $(97.6) million |
| Net loss per share | $(4.56) | $(2.95) |
| Net cash used in operating activities | $(134.1) million | $(78.5) million |
- Fourth-quarter 2016 net product sales were $1.279 million, with a net loss of $48.0 million and a loss from operations of $46.8 million.
- Reported product gross margin was approximately 97%, but it is not representative of normalized economics because all SUSTOL units sold were manufactured before approval and their manufacturing costs had previously been expensed in research and development.
- Cash, cash equivalents and short-term investments totaled $51.1 million at year-end, down from $131.2 million at December 31, 2015. Working capital was $23.4 million.
- Total liabilities were $88.7 million and stockholders’ equity was negative $21.3 million. The accumulated deficit was $586.0 million.
- Management stated that year-end resources were sufficient to fund operations for at least one year from the filing date. Following year-end, a January 2017 equity offering generated $163.7 million of net proceeds, producing pro forma liquidity of $214.8 million.
Material changes versus the prior comparable period
- 2016 was the first year with product revenue, following SUSTOL’s October commercial launch; $1.1 million of shipments to distributors remained deferred because the company lacked sufficient data to estimate returns, rebates and ultimate utilization reliably.
- Research and development expense increased 69% to $103.1 million, driven primarily by HTX-011 clinical and manufacturing costs, higher headcount, stock-based compensation, CINVANTI development and new product development. SUSTOL-related development costs declined after completion of its Phase 3 program.
- Sales and marketing expense increased 175% to $47.7 million as Heron hired and trained a commercial sales force and prepared for the SUSTOL launch.
- Operating cash use increased by $55.6 million, reflecting launch preparation, HTX-011 development and CINVANTI activities.
- Heron entered into a $50.0 million related-party subordinated secured promissory note in August 2016 at 8% interest. A second $50.0 million tranche remained contingent on achieving a corporate milestone.
- The company realigned its objectives after SUSTOL approval and refocused development efforts on post-operative pain. The realignment generated $7.8 million of expense in 2016, with total anticipated expenses of $10.4 million.
Pipeline, outlook and key risks
- SUSTOL: Commercialization is the principal near-term revenue driver, but adoption depends on physician acceptance, reimbursement, formulary access, competition, pricing and continued manufacturing and supply performance.
- CINVANTI: Heron submitted a 505(b)(2) NDA to the FDA on January 11, 2017. Management expected commercial availability in the first quarter of 2018 if approved.
- HTX-011: Phase 2 studies reported positive efficacy and safety results. Heron anticipated initiating Phase 3 studies in 2017 and filing an NDA in 2018; these milestones remained subject to regulatory, clinical and funding risks.
- Research and development expense and sales and marketing expense were expected to increase in 2017 to support HTX-011 Phase 3 preparation, SUSTOL post-marketing requirements, CINVANTI pre-commercialization and ongoing commercialization.
- Heron relies on a limited number of third-party manufacturers, including single suppliers for certain critical components, and does not own manufacturing facilities.
- The company had significant continuing losses and negative operating cash flow and may require additional financing. Debt is secured by substantially all assets and includes operational restrictions.
- The $6.0 million principal amount of convertible notes could convert into approximately 7.5 million shares, creating substantial dilution. The notes bear 6% interest and may be subject to holder-requested prepayment.
- Three specialty distributors each represented at least 10% of 2016 net revenue, creating customer concentration risk.
- Other risks include regulatory approval and post-marketing obligations, clinical-trial failure, product liability, reimbursement pressure, competition, patent challenges, manufacturing disruptions and potential loss or limitation of tax attributes.
- The independent auditor issued an unqualified opinion, and management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2016.
Most important facts for investors to verify
- Progression of SUSTOL sales from distributor shipments to end-user utilization, including deferred revenue, returns, rebates and chargebacks.
- 2017 and subsequent cash burn relative to the $214.8 million pro forma liquidity figure and the company’s stated funding horizon.
- Achievement of the milestone required to access the additional $50.0 million under the promissory note.
- FDA review and outcome of the CINVANTI NDA, including labeling, timing and commercial launch assumptions.
- HTX-011 Phase 3 design, enrollment, results and NDA timing.
- Gross margin after capitalization of SUSTOL manufacturing costs begins to affect cost of product sales.
- Potential dilution and cash obligations associated with convertible notes, stock options, warrants and future equity financing.
- Reliability of third-party manufacturing, supply arrangements and distributor concentration.